HappyLibrarian,
The whole “there needs to be another trial” argument being bandied about falls flat on it’s face in light of the fact that regulators had a hand, indirect or not, in keeping the last 17 SOC/placebo patients out of this trial. You do understand the ramifications of only enrolling to the point statistically necessary mentioned by Fraunhofer and how that messes with the trial right? Oh how some of us are so quick to forget, underestimate, dismiss and doubt because of uncertainty and fear created by our questions ; ). Best wishes.
Market Data 
Markets 
AI
